Press "Enter" to skip to content

‘None of This Matters’: What We Heard This Week

“She looked me straight in the face and she said, ‘None of this matters … nothing matters,'” — Rhonda Simpson, RN, discussing the suicide of a fellow nurse.

“I would consider that a small effect that is of questionable clinical relevance.” — Elizabeth Loder, MD, of Brigham and Women’s Hospital, on one of the outcomes of a new migraine therapy.

“The Republican Party is very much becoming the party of healthcare.” — President Donald Trump, announcing an initiative to address the issue of “surprise” medical billing.

“From that perspective, it is kind of exciting.” — Benjamin Davies, MD, of the University of Pittsburgh Medical Center, discussing a study on immunotherapy for patients with bladder cancer.

“This would be a wonderful, slam-dunk study if the sham eye didn’t improve as well.” — Mark Moster, MD, of Wills Eye Hospital, on surprising results with a novel gene therapy for a rare eye disease.

“The million dollar question — or perhaps more, given the cost of these drugs — is really the durability of these responses.” — Sarah Holstein, MD, PhD, of the University of Nebraska Medical Center in Omaha, on CAR T-cell therapies in multiple myeloma.

“It’s not the savior for women with fibroids.” — Charles Ascher-Walsh, MD, of Icahn School of Medicine at Mount Sinai in New York City, on a potential new treatment for uterine fibroids.